Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 287, Issue 3 31-3, 2004, Pages

  Pauvert, Olivier ^a   Bonnet, Sébastien ^a   Rousseau, Eric ^b   Marthan, Roger ^a   Savineau, Jean Pierre ^a,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c INSERM   (France)

Author keywords

Phosphodiesterase 5; Pulmonary hypertension; Pulmonary vasodilator; Vascular smooth muscle

Indexed keywords

ANGIOTENSIN; CAFFEINE; CALCIUM; CALCIUM FLUOROPHORE; CALCIUM IONOPHORE; G COUPLED MEMBRANE RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTERY MUSCLE; ARTERY TONE; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; EXPERIMENTAL MODEL; HYPOXIA; LUNG ARTERY; MALE; MICROFLUOROMETRY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RAT STRAIN; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANGIOTENSIN II; ANIMALS; ANOXIA; CAFFEINE; CALCIUM; CALCIUM SIGNALING; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; MALE; MUSCLE, SMOOTH, VASCULAR; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY ARTERY; RATS; RATS, WISTAR; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 4143121002     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00449.2003     Document Type: Article

References (48)

1. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, and Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isosymes. J Urol 159: 2164-2171, 1998.
2. Barberà JA, Peinado VI, and Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 21: 892-905, 2003.
3. Barnes PJ and Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev 47: 87-131, 1995.
4. Bialecki RA, Fisher CS, Murdoch WW, Barthlow HG, Stow RB, Mallamaci M, and Rumsey W. Hypoxic exposure time dependently modulates endothelin-induced contraction of pulmonary artery smooth muscle. Am J Physiol Lung Cell Mol Physiol 274: L552-L559, 1998.
5. Bonnet S, Belus A, Hyvelin JM, Roux E, Marthan R, and Savineau JP. Effect of chronic hypoxia on agonist-induced tone and calcium signaling in rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 281: L193-L201, 2001.
6. Bonnet S, Dubuis E, Vandier C, Marthan R, and Savineau JP. Reversal of chronic hypoxia-induced alterations in pulmonary artery smooth muscle electromechanical coupling upon air breathing. Cardiovasc Res 53: 1019-1028, 2002.
7. Bonnet S, Hyvelin JM, Bonnet P, Marthan R, and Savineau JP. Chronic hypoxia-induced spontaneous and rhythmical contractions in the rat main pulmonary artery. Am J Physiol Lung Cell Mol Physiol 281: L183-L192, 2001.
8. Boolell M, Gepi-Attee S, Gingell JC, and Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78: 257-261, 1996.
9. Carvajal JA, Germain AM, Huidobro-Toro JP, and Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 184: 409-420, 2000.
10. 3H] Sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 63: 1364-1372, 2003.
11. Cornvell TL, Pryzwansky KB, Wyatt TA, and Lincoln TM. Regulation of sarcoplasmic reticulum protein phosphorylation by localised cyclic GMP-dependent protein kinase in vascular smooth muscle cells. Mol Pharmacol 40: 923-931, 1991.
12. Dawson CA. Role of pulmonary vasomotion in physiology of the lung. Physiol Rev 64: 544-616, 1984.
13. Fabiato A. Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. Methods Enzymol 157: 378-417, 1988.
14. 2+ pump blockers: thapsigargin and cyclopiazonic acid. Pflügers Arch 429: 617-624, 1995.
15. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450, 1985.
16. Guibert C, Marthan R, and Savineau JP. Angiotensin II-induced Ca(2+)-oscillations in vascular myocytes from the rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 270: L637-L642, 1996.
17. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, and Clarke WR. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 158: 279-288, 1998.
18. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, and Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol Lung Cell Mol Physiol 275: L931-L941, 1998.
19. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, Clark MW, Winkler JD, Bloch KD, and Zapol WM. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29: 1000-1005, 2001.
20. Komalavilas P and Lincoln TM. Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic GMP-dependent protein kinase. J Biol Chem 269: 8701-8707, 1994.
21. Komas N, Lugnier C, and Stoclet JC. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 104: 495-503, 1991.
22. Lincoln TM and Cornvell TL. Intracellular cyclic GMP receptor proteins. FASEB J 7: 328-338, 1993.
23. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, and Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283: 619-624, 1997.
24. Marthan R, Castaing Y, Manier G, and Guenard H. Gas exchange alterations in patients with chronic obstructive lung disease. Chest 87: 470-475, 1985.
25. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation 105: 2398-2403, 2002.
26. Michelakis E, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, and Archer S. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108: 2066-2069, 2003.
27. Murray F, MacLean MR, and Pyne NJ. Increased expression on the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137: 1187-1194, 2002.
28. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, and Oka M. Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. In press.
29. Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, and Savineau JP. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br J Pharmacol 139: 513-522, 2003.
30. Pauvert O, Marthan R, and Savineau JP. NO-induced modulation of calcium-oscillations in pulmonary vascular smooth muscle. Cell Calcium 27: 329-338, 2000.
31. Pauvert O, Savail D, Rousseau E, Lugnier C, Marthan R, and Savineau JP. Characterization of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 63: 1763-1772, 2002.
32. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia. Respir Care 45: 39-51, 2000.
33. V channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol 280: L801-L812, 2001.
34. Polson JB and Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36: 403-427, 1996.
35. Priest RM, Hucks D, and Ward JPT. Potentiation of cyclic AMP-mediated vasorelaxation by phenylephrine in pulmonary arteries of the rat. Br J Pharmacol 127: 291-299, 1997.
36. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, and Magnussen H. Identification of PDE isoenzymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol Lung Cell Mol Physiol 266: L536-L543, 1994.
37. Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, and Reid L. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol Heart Circ Physiol 236: H818-H827, 1979.
38. Savineau JP, Gonzalez de la Fuente P, and Marthan R. Effect of vascular smooth muscle relaxants on the protein kinase C-mediated contraction in the rat pulmonary artery. Eur J Pharmacol 249: 191-198, 1993.
39. Savineau JP and Marthan R. Cytosolic calcium oscillations in smooth muscle cells. News Physiol Sci 15: 50-55, 2000.
40. Sauzeau V, Rolli-Dirkinderen M, Lehoux S, Loirand G, and Pacaud P. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res 93: 630-637, 2003.
41. Schoeffter P, Lugnier C, Demesy-Waeldele F, and Stoclet JC. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem Pharmacol 36: 3965-72, 1987.
42. Sebkhi A, Strange JW, Phillips SC, Wharton J, and Wilkins MP. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107: 3230-3235, 2003.
43. 2+], and ET-1-induced responses in chronically hypoxic pulmonary myocytes. Am J Physiol Lung Cell Mol Physiol 279: L884-L894, 2000.
44. Stoclet JC, Keravis TH, Komas N, and Lugnier C. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. Exp Opin Invest Drugs 4: 1081-100, 1995.
45. + ATPase in cyclic GMP-mediated relaxation of canine pulmonary artery smooth muscle cells. Br J Pharmacol 122: 112-116, 1997.
46. Wagner RS, Smith CJ, Taylor A, and Roades RA. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 282: 1650-1657, 1997.
47. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, Böhm M, and Sybrercht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104: 1218-1222, 2001.
48. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, and Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 24: 424-428, 2001.